Expansion into Workers' Comp RelieVRx has been launched specifically for workers' compensation programs, indicating a ready-made sales path with payers, physicians, and claimants in that sector. Targeting insurer and TPAs managing workers' comp portfolios could accelerate adoption and scale.

FDA Milestones RelieVRx is FDA Breakthrough Device Designation and De Novo authorized for chronic lower back pain, signaling strong regulatory validation and credibility. Use this to position the product as a clinically validated, preferred non-pharmacological option to reduce opioid reliance in pain management programs.

CMS and Coverage Momentum The platform has achieved a unique CMS code and coverage category, suggesting favorable reimbursement pathways. Focus conversations on payer feasibility and dispersion of costs through existing reimbursement structures to shorten time-to-value for customers.

Clinical Evidence Base Clinical trials involving over 1,200 patients demonstrate reductions in pain and pain intensity. Leverage the robust evidence to approach hospitals, clinics, and integrated health systems seeking validated non-drug therapies for chronic lower back pain and related conditions.

Strategic Partnerships Past collaborations with Veterans Affairs and health systems indicate openness to large, government-connected buyers and integrating ITx solutions into multi-site programs. Propose pilots or expanded deployments with VA-affiliated facilities, large health networks, and workers' compensation providers.